LONDON, February 9, 2012 /PRNewswire/ -- Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, today announced the results of a new study for its BIRMINGHAM HIP™ Resurfacing (BHR) System. The study, carried out at the request of the FDA, followed the progress of the first 400 BHR patients in the United Kingdom and found that after 10 years, 99% were either satisfied or extremely satisfied with their BHR procedure.
"These results further exemplify why the BHR Hip is unlike any other metal-on-metal implant," says John Soto, Senior Vice President for Smith & Nephew's Global Hip Franchise. "Not only does the BHR Hip offer all the advantages of hip resurfacing, including bone-conservation, greater range of motion and decreased risk of dislocation, but it does so while maintaining implant survivorship rates that are on par with, or in some patient populations even better than, traditional total hip replacement which has long been considered the most successful orthopaedic surgical procedure for relieving chronic pain."
In addition to patient satisfaction, the 10-year BHR data showed:
- The Oswestry Modified Harris Hip Score (OMHHS) averaged 92.5 points – demonstrating excellent long-term clinical implant function.[i]
- The implant survival rate according to the Kaplan-Meier analysis was 95.9% - well exceeding the 10-year survivorship threshold of 90% for implants as established by the National Institute for Health and Clinical Science (NICE)[ii]
- A radiographic success rate of 99.7% was observed by independent radiographic review.